|
Neratinib Clinical Trials
11 actively recruiting trials across 7 locations
▲ +1 trial since May 2026
Also known as: NERLYNX, Nerlynx
Pipeline
Phase 2: 8Phase 3: 1Phase 1/2: 1
Top Sponsors
- Virginia Commonwealth University1
- Vanderbilt-Ingram Cancer Center1
- University Health Network, Toronto1
- UNICANCER1
- Shu Wang1
Indications
- Cancer11
- Breast Cancer6
- HER2-positive Breast Cancer4
- Non-vestibular Schwannoma1
- Neurofibromatosis Type 21
Other3 trials
Birmingham, Alabama2 trials
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
University of Alabama at Birmingham
Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
University of Alabama at Birmingham
Phase 2
Los Angeles, California1 trial
Tampa, Florida1 trial
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Moffitt Cancer Center
Phase 2
Atlanta, Georgia1 trial
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Emory University/ Winship Cancer Institute
Phase 2
Chicago, Illinois1 trial
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
University of Illinois Cancer Center
Phase 2
Lebanon, New Hampshire1 trial
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Dartmouth Hitchcock Medical Center
Phase 2
Richmond, Virginia1 trial
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University Massey Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.